AstraZeneca plc (LON:AZN) declared a dividend on Friday, February 14th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, February 27th will be paid a dividend of GBX 146.40 ($1.93) per share by the biopharmaceutical company on Monday, March 30th. This represents a yield of 1.92%. The ex-dividend date of this dividend is Thursday, February 27th. This is a positive change from AstraZeneca’s previous dividend of $71.90. The official announcement can be accessed at this link.

LON:AZN traded down GBX 288 ($3.79) during trading hours on Friday, hitting GBX 7,338 ($96.53). 2,048,936 shares of the stock traded hands, compared to its average volume of 2,310,000. The company has a quick ratio of 0.70, a current ratio of 0.92 and a debt-to-equity ratio of 148.59. AstraZeneca has a 1 year low of GBX 109.51 ($1.44) and a 1 year high of GBX 8,227.88 ($108.23). The company has a market cap of $100.07 billion and a price-to-earnings ratio of 46.04. The stock has a 50 day moving average price of GBX 7,668.20 and a 200 day moving average price of GBX 7,328.85.

Several brokerages have weighed in on AZN. UBS Group reaffirmed a “sell” rating and set a GBX 5,800 ($76.30) price target on shares of AstraZeneca in a report on Monday, February 3rd. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a report on Friday. Liberum Capital reissued a “buy” rating on shares of AstraZeneca in a report on Friday. Deutsche Bank reissued a “buy” rating and issued a GBX 8,400 ($110.50) target price on shares of AstraZeneca in a report on Tuesday, January 28th. Finally, Bryan, Garnier & Co reissued a “buy” rating on shares of AstraZeneca in a report on Thursday, December 19th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of GBX 7,912.14 ($104.08).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: P/E Growth (PEG)

Dividend History for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.